Nyxoah Shares Hit a New All-Time Low at 3.21 Euros
This Friday, Nyxoah recorded a new all-time low during the session, at 3.21 euros, before making a slight recovery. The stock of the Belgian medtech company specializing in sleep apnea treatment is now trading at 3.245 euros, marking a symbolic increase of 0.31% from the previous day. The upcoming publication of the 2025 annual results on March 19 is a major upcoming event for the stock.
Continued Downward Trajectory for Nyxoah Shares
During the session, Nyxoah's stock broke its previous historical low of 3.21 euros, set on March 4th. This new low is part of a continuous downward trajectory: the stock has declined by 13.12% over the past seven days and by 24.18% over three months. Over the year, the loss reaches 65.84%, highlighting the significant deterioration of the value. The technical momentum confirms this persistent selling pressure. The stock is trading well below its 50-day (4.01 euros) and 200-day (5.09 euros) moving averages, indicating an unfavorable underlying trend. The RSI, a momentum indicator measuring market extremes, is at 28, below the generally considered oversold threshold of 30. This level signals intense bearish pressure, although it does not mechanically predict a reversal.
Upcoming Catalysts for Nyxoah Stock
The next identified catalyst for the stock is the publication of the annual results, scheduled for March 16 for a preliminary release, followed by March 19 for the full accounts of the 2025 fiscal year. This upcoming deadline could provide market participants with concrete details on the company's operational and financial trajectory, particularly regarding the progress of its medical devices for the treatment of obstructive sleep apnea. Beyond this publication, the financial calendar includes the results for the first quarter of 2026 on May 12, followed by the annual general meeting scheduled for June 10. The technical support threshold is at 3.24 euros, a level tested during today's session, while the nearest resistance is positioned at 4.23 euros, nearly 30% above the current price. The stock's relatively low volatility compared to the market, with a beta of 0.22, however, indicates that its movements remain weakly correlated with general market fluctuations.
